Povorcitinib
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Povorcitinib
- Molecular weight
- 507.47
- Structure (SMILES)
- Cc1n[nH]c(C)c1-c1cnn(C2(CC#N)CN(c3cc(F)c(C(=O)N[C@@H](C)C(F)(F)F)cc3F)C2)c1
- incb 054707
- INCB-054707
- incb054707
- Incb054707
- INCB054707
- povorcitinib
- Povorcitinib
- povorcitinib [INN]
- POVORCITINIB [USAN]
- Povorcitinib [WHO-DD]
- povorcitinib inn
- povorcitinib usan
- povorcitinib who dd
- CAS registry numbers
- 1637677-22-5
- ChEMBL ID
- CHEMBL5095079
- InChIKey
- MSGYSFWCPOBHEV-AWEZNQCLSA-N
- PubChem compound IDs
- 86280672
- FDA ingredient codes (UNII)
- N0JWC7RO00
- Status
- opinion
- Status date
- 17 Sept 2026
- Approved indications
- Treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults
- Product number
- EMEA/H/C/006727
- Authorisation holder
- Incyte Biosciences Distribution B.V.
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Hidradenitis Suppurativa
European medicines record
- First in class
- No
- Orphan designation
- No
- European Union (EMA)
- Opinion adopted, decision pending
- Pharmacology name
- povorcitinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Janus kinase 1
- Gene symbol
- JAK1
- Protein identifier
- P23458
- Median affinity
- 6.52
- Affinity units
- pIC50
- Condition
- Vitiligo
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004208
- Subject identifier
- D014820
- Condition
- Hidradenitis Suppurativa
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000710
- Subject identifier
- D017497
- Condition
- Asthma
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition
- Prurigo
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0021739
- Subject identifier
- D011536
- Condition identifier
- EFO_0004208
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000710
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006559
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008661
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0021739
- Condition identifier
- MONDO_0026045
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0044212
- Highest recorded phase
- 2
- NCT03569371
- NCT03607487
- NCT04476043
- NCT05620823
- NCT05620836
- NCT06212999
- NCT04818346
- NCT06113445
- NCT06113471
- NCT05851443
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 102.63
- Calculated partition coefficient (ALogP)
- 3.98
- Calculated partition coefficient (XLogP)
- 3.1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 6
- Heavy atoms
- 36
- Molecular formula
- C23H22F5N7O
- Monoisotopic mass
- 507.18059916
- Natural product
- No
Related records
Trials (24)
- A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
- A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
- A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
- A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
- A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
- A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
- A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants
- A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females
- A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants
- A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
- A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
- A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
- A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
- A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
- A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707
- Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
In development for (6)
- Asthma Phase 2
- Chronic idiopathic urticaria Phase 2
- Hidradenitis suppurativa Phase 3
- Prurigo Phase 1
- Prurigo nodularis Phase 3
- Vitiligo Phase 3